Atlas Trials

Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Clinical trial NCT05349214 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05349214
Sponsor
Novartis Pharmaceuticals
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Sjogren Syndrome
Start date
2022-08-04
Primary completion
2025-05-13
Enrollment
506

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.